Bridging Across Indications/Products


Published on 29/11/2025

Bridging Across Indications/Products in Biologics and ATMP Validation

The landscape of biologics and advanced therapy medicinal products (ATMPs) validation poses intricate challenges, particularly in the areas of process performance qualification (PPQ) and continued process verification (CPV). This article serves as a comprehensive step-by-step tutorial, tailored for pharmaceutical professionals, regulatory affairs, and clinical operations personnel engaged in the validation of ATMPs, emphasizing viral clearance validation, closed systems, single-use systems, and aseptic controls as per Annex 1 guidelines. We will discuss key elements such as potency identity, the chain of identity custody, and the significance of spiking studies. By following this guide, you will ensure compliance with US, UK, and EU regulatory frameworks, including FDA and EMA guidelines.

Understanding Process Performance Qualification (PPQ)

Process Performance Qualification (PPQ) is a critical phase within the validation lifecycle of biologics and ATMPs. It is designed to confirm that the manufacturing process is capable of consistently producing a product that meets its predetermined specifications. In this section, we will outline the steps necessary to develop an effective PPQ strategy.

Step 1: Define Product Quality Attributes (PQAs)

  • Identify CQAs: Begin with a thorough identification of Critical Quality Attributes (CQAs) that define the desired characteristics of the product. This may include potency, identity, purity, and sterility. Ensuring that CQAs are aligned with regulatory expectations, such as those outlined by FDA, is paramount.
  • Regional Considerations: Acknowledge variations in expectations across different jurisdictions. For instance, the EMA and MHRA may have specific guidelines relevant to the oversight of CQAs.

Step 2: Develop a PPQ Plan

The development of a PPQ plan entails defining the scope, methodologies, and acceptance criteria. Consider the following elements:

  • Scope: Clearly delineate which processes and products the PPQ will cover. For ATMPs, focus on unique aspects relating to the complexity and variability of biologic products.
  • Methodologies: Determine the methodologies to be employed, such as statistical tools for data analysis or specific techniques for product characterization.
  • Acceptance Criteria: Define what constitutes acceptance for each CQA. Criteria should be based on historical results or regulatory benchmarks.

Step 3: Execute Qualification Studies

Executing the qualification studies involves performing experiments or tests to verify that the process meets the established criteria. Key activities during this phase may include:

  • Batch Production: Producing multiple batches of product under the defined conditions to assess consistency and reliability.
  • Elite Validation Tests: Implement specialized tests designed for ATMPs, focusing on attributes such as potency identity and sterility.

The Critical Role of Viral Clearance Validation

Viral clearance validation is a pivotal component in ensuring product safety, particularly within biologics and ATMPs. This process assesses the ability of the manufacturing process to eliminate or inactivate viruses and other contaminants.

Step 1: Understand Regulatory Expectations

Familiarize yourself with key guidelines, such as EMA and ICH Q5A(R2). These documents outline fundamental principles for viral safety, emphasizing the need for a robust viral clearance strategy.

Step 2: Design Viral Clearance Studies

Viral clearance studies should be designed to challenge various aspects of the production process:

  • Spiking Studies: Incorporate spiking studies where known viruses are introduced into the process. Assess how effectively the manufacturing steps can reduce viral load.
  • Environmental Considerations: Ensure that virus risks linked to raw materials, equipment, and closed systems are minimized.

Step 3: Analyze Results and Validate

Upon completion of viral clearance studies, analyze the data to validate that viral removal or inactivation is achieved. Discussions should include:

  • Data Interpretation: Interpret results in line with acceptance criteria established during the planning phase.
  • Regulatory Submission: Prepare documentation for regulatory bodies, detailing methodologies, results, and justifications for clearance claims.

Implementing Closed Systems and Single-Use Technologies

The use of closed systems and single-use technologies offers significant advantages for aseptic processing in ATMP manufacturing. Their integration can enhance contamination control and streamline operations. However, their validation must be thoroughly planned and executed.

Step 1: Identify System Requirements

Establish critical parameters for closed systems and single-use systems to validate their effectiveness in maintaining sterility:

  • System Design: Evaluate the design to ensure it minimizes risks associated with contamination while allowing seamless integration into the production flow.
  • Materials Compatibility: Confirm that materials used in single-use systems are compatible with the intended use and do not leach harmful substances.

Step 2: Establish Validation Protocols

Your validation protocols should encompass several key elements:

  • Performance Testing: Test systems under worst-case scenarios to ensure efficacy.
  • Qualifying Suppliers: Qualify all suppliers and perform audits to guarantee compliance with quality levels that correspond to your validation expectations.

Step 3: Monitor and Continually Validate

Validation does not end once systems are implemented. Continuous monitoring is critical:

  • Periodic Review: Review performance data periodically to assess system reliability and any potential need for revalidation.
  • Adaptation to Changes: Be prepared to adapt your validation plans based on new technologies or changes in regulatory expectations, especially those stipulated in Annex 1.

Aseptic Controls in Accordance with Annex 1

Compliance with aseptic controls outlined in Annex 1 is essential for ensuring the safety and quality of sterile medicinal products, especially in the realm of ATMPs. This section discusses critical steps to meet these controls.

Step 1: Implement Environmental Monitoring

Environmental monitoring is fundamental to maintaining the integrity of aseptic manufacturing:

  • Monitoring Plans: Develop comprehensive monitoring plans, focusing on viable and non-viable particles in manufacturing areas.
  • Alarming and Responsive Measures: Institute systems for rapid response to environmental excursions. Ensure adequate training for personnel to respond to contamination risks.

Step 2: Assess Aseptic Process Validation

Aseptic process validation (APV) must be a core component of the validation strategy:

  • Media Fill Studies: Conduct media fill studies to simulate the entire filling process. Document results to ensure that processes are aseptically maintained.
  • Validation of Equipment and Facility: Validate all equipment used in the aseptic process and confirm that facility designs mitigate contamination risks.

Step 3: Training and Personnel Qualification

Human factors play a critical role in aseptic manufacturing:

  • Training Programs: Create comprehensive training programs that emphasize aseptic techniques and contamination control.
  • Personnel Behavior Monitoring: Regularly assess personnel behaviors to maintain a culture of quality and safety in aseptic environments.

Navigating Transition to Commercialization

The transition from development to commercialization introduces additional complexities requiring rigorous quality assurance:

Step 1: Regulatory Submission Strategies

Engage early with regulatory authorities to align on validation requirements:

  • Pre-Submission Meetings: Consider holding pre-submission meetings to gain clarity on submission expectations in relation to validation data.
  • Submission Size and Complexity: Prepare to submit extensive validation documentation, clearly delineating methodologies, results, and justifications for processes.

Step 2: Post-Approval Commitments

After approval, maintaining efficacy through continued validation and compliance activities is essential:

  • Annual Reports: Maintain compliance through annual reports that summarize manufacturing performance, including insights gained from continued process verification.
  • Continuous Improvement: Create a culture of continual improvement based on findings from CPV and make the necessary adjustments to processes as required.

Conclusion

In conclusion, bridging across indications and products in the validation of ATMPs involves a meticulous approach to PPQ, viral clearance validation, aseptic controls, and risk mitigation strategies using closed and single-use systems. By adhering to a structured methodology, pharmaceutical professionals can ensure compliance with regulatory standards set forth by authorities such as FDA, EMA, and MHRA.

Such diligence not only satisfies regulatory requirements but also safeguards the safety and efficacy of biologics and ATMPs, ultimately benefiting patients and advancing pharmaceutical science.